Skip to main content

Advertisement

SpringerLink
Log in

Effect of graft sources on allogeneic hematopoietic stem cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

We retrospectively compared transplant outcomes for related bone marrow transplantation (rBMT), related peripheral blood stem cell transplantation (rPBSCT), unrelated bone marrow transplantation (uBMT), and unrelated cord blood transplantation (CBT) in 1,062 patients with chronic myeloid leukemia (CML) aged 20 years or over between January 1, 2000 and December 31, 2009 in Japan. The disease status was as follows: chronic phase 1 (CP1, n = 531), CP 2 or later including accelerated phase (CP2-AP, n = 342) and blastic crisis (BC, n = 189). Graft sources (GS) were rBMT (n = 205), uBMT (n = 507), rPBSCT (n = 226) or CBT (n = 124). In multivariate analysis in CP1, lower overall survival (OS) (relative risk [RR]: 6.01, 95 % confidence interval [CI]: 1.20–29.97, P = 0.029) and leukemia-free survival (LFS) (RR: 4.26, 95 % CI: 1.24–14.62, P = 0.021) were observed in uBMT compared with those in rBMT. For patients in the advanced phase of CML beyond CP1, GS had no significant impact on OS or LFS. Our results support the use of rBMT for adults with CML in CP1, but in contrast to previous reports, the superiority of rPBSCT in advanced stage of CML was not confirmed in our cohorts.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Cortes J, H Kantarjian. How I treat newly diagnosed chronic phase CML. Blood. 2012;120:1390–7.

    Article  CAS  PubMed  Google Scholar 

  2. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041–51.

    Article  CAS  PubMed  Google Scholar 

  3. Hehlmann R, Berger U, Pfirrmann M, et al. Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia. Blood. 2007;109:4686–92.

    Article  CAS  PubMed  Google Scholar 

  4. Saussele S, Lauseker M, Gratwohl A, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood. 2010;115:1880–5.

    Article  CAS  PubMed  Google Scholar 

  5. Radich J. Stem cell transplant for chronic myeloid leukemia in the imatinib era. Semin Hematol. 2010;47:354–61.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Venepalli N, Rezvani K, Mielke S, et al. Role of allo-SCT for CML in 2010. Bone Marrow Transpl. 2010;45:1579–86.

    Article  CAS  Google Scholar 

  7. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367:2075–88.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16:401–12.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Atsuta Y, Suzuki R, Yoshimi A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol. 2007;86:269–74.

    Article  PubMed  Google Scholar 

  10. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825–8.

    CAS  Google Scholar 

  11. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28:250–9.

    CAS  PubMed  Google Scholar 

  12. Kanda J. Effect of HLA mismatch on acute graft-versus-host disease. Int J Hematol. 2013;98:300–8.

    Article  CAS  PubMed  Google Scholar 

  13. Gratwohl A, Brand R, Apperley J, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2006;91:513–21.

    PubMed  Google Scholar 

  14. Khoury HJ, Kukreja M, Goldman JM, et al. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transpl. 2012;47:810–6.

    Article  CAS  Google Scholar 

  15. Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2000;95:3702–9.

    CAS  PubMed  Google Scholar 

  16. Oehler VG, Radich JP, Storer B, et al. Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. Biol Blood Marrow Transpl. 2005;11:85–92.

    Article  Google Scholar 

  17. Lee SJ, Kukreja M, Wang T, et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood. 2008;112:3500–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Oehler VG, Gooley T, Snyder DS, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood. 2007;109:1782–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Perz JB, Khorashad JS, Marin D, et al. Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia. Haematologica. 2006;91:1145–6.

    PubMed  Google Scholar 

  20. Giralt SA, Arora M, Goldman JM, et al. Chronic Leukemia Working Committee, Center for International Blood and Marrow Transplant Research. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol. 2007;137:461–7.

    Article  CAS  PubMed  Google Scholar 

  21. Deininger M, Schleuning M, Greinix H, et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica. 2006;91:452–9.

    CAS  PubMed  Google Scholar 

  22. Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med. 1997;337:373–81.

    Article  CAS  PubMed  Google Scholar 

  23. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 1998;339:1565–77.

    Article  CAS  PubMed  Google Scholar 

  24. Sanz GF, Saavedra S, Jimenez C, et al. Unrelated donor cord blood transplantation in adults with chronic myelogenous leukemia: results in nine patients from a single institution. Bone Marrow Transpl. 2001;27:693–701.

    Article  CAS  Google Scholar 

  25. Nagamura-Inoue T, Kai S, Azuma H, et al. Unrelated cord blood transplantation in CML: Japan Cord Blood Bank Network analysis. Bone Marrow Transpl. 2008;42:241–51.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We thank all of the physicians and nurses who cared for patients in this study. We also thank all the data managers and officers of the JSHCT, JMDP, and JCBBN.

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Hematology Division, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Japan

    Kazuteru Ohashi & Hisashi Sakamaki

  2. Department of Cell Processing and Transfusion, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

    Tokiko Nagamura-Inoue

  3. Division of Clinical Trial Safety Management, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

    Fumitaka Nagamura

  4. Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

    Arinobu Tojo

  5. Department of Hematology, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan

    Kouichi Miyamura

  6. Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan

    Takehiko Mori

  7. Department of Cell Therapy and Transplantation Medicine, The University of Tokyo, Tokyo, Japan

    Mineo Kurokawa

  8. Department of Hematology, Toranomon Hospital, Tokyo, Japan

    Shuichi Taniguchi

  9. Department of Hematology and Chemotherapy, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan

    Jun Ishikawa

  10. Division of Epidemiology/Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan

    Yasuo Morishima

  11. Department of HSCT Data Management/Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Yoshiko Atsuta

  12. Japan Cord Blood Bank Network, Tokyo, Japan

    Tokiko Nagamura-Inoue

  13. Japan Marrow Donor Program, Tokyo, Japan

    Yasuo Morishima

  14. Japanese Society of Hematopoietic Cell Transplantation, Nagoya, Japan

    Yoshiko Atsuta & Hisashi Sakamaki

Authors
  1. Kazuteru Ohashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tokiko Nagamura-Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fumitaka Nagamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arinobu Tojo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kouichi Miyamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takehiko Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mineo Kurokawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shuichi Taniguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jun Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yasuo Morishima
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yoshiko Atsuta
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hisashi Sakamaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kazuteru Ohashi.

Additional information

On behalf of Choric Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (XLSX 13 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ohashi, K., Nagamura-Inoue, T., Nagamura, F. et al. Effect of graft sources on allogeneic hematopoietic stem cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis. Int J Hematol 100, 296–306 (2014). https://doi.org/10.1007/s12185-014-1632-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-014-1632-9

Keywords

Search

Navigation